Valganciclovir

This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCU97FKN3R. European Medicines Agency schedules Valganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00007MIG. Valganciclovir generally arises in the molecular formula C14H22N6O5. The term VALGANCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) VALGANCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valganciclovir under HS 29335995 and SITC 51576. As of Q4 2014, VALGANCICLOVIR remains the US FDA Preferred Term for this commodity. Valganciclovir bears US NLM identifiers UMLS ID C0909381 and NCI Concept Code C2629. SMILES: CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1NC(=NC2=O)N)N.